Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
MedPlus Health Services' subsidiary Optival Health Solutions Private Limited received a 3-day suspension order for the drug license of one store located at Sulibele Road, Devanahalli, Karnataka. The order was issued by the Assistant Director, Drugs Control Administration, Bangalore Circle on August 10, 2025, under Rule 65 of the Drugs and Cosmetics Act, 1940. The financial impact is estimated at approximately Rs 0.87 lacs in potential revenue loss. This is a routine regulatory compliance disclosure filed under SEBI Listing Regulations.
Negligible impact on shareholders — the revenue loss is minimal (~Rs 87,000), involves only a single store, and the suspension is short-term (3 days). No material effect on overall business or stock price expected.